Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Upgraded by Zacks Research to “Hold” Rating

Posted by Joseph Casey on May 27th, 2026

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Hold”.

View Our Latest Stock Report on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

OTCMKTS SGIOY opened at $9.33 on Monday. The company’s 50 day moving average is $10.23 and its 200-day moving average is $9.86. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.65 and a 12-month high of $12.00. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The firm has a market cap of $15.88 billion, a P/E ratio of 11.66, a price-to-earnings-growth ratio of 0.68 and a beta of 0.10.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The company had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. Sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.